Drug Trial Radar · NCT00802373
Solifenacin Succinate Versus Tolterodine 4mg Once Daily
Last checked: Nov 20, 2026Latest source record: Sep 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,355
Actual
Start
Jul 2003
Primary completion
Oct 2004
Study completion Oct 2004
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Dec 4, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, double-blind, double-dummy, 2-arm, parallel-group, design. Flexible dose regimen for solifenacin succinate, fixed dose treatment regimen for tolterodine. Assessment of OAB symptoms by patient diaries.
Conditions
- Urinary Bladder, Overactive
Interventions
Solifenacin succinateDrug
oral
TolterodineDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in mean number of micturitions per 24 hoursTime frame: Weeks 4, 8 and 12
Locations
95 sites in 17 countries. Site status is shown where the registry gives one.
Site not named
Minsk, Belarus
Site not named
Antwerp, Belgium
Site not named
Brussels, Belgium
Site not named
Ghent, Belgium
Site not named
Middleheim, Belgium
Site not named
Brno, Czechia
Site not named
Bulovce, Czechia
Site not named
České Budějovice, Czechia
Site not named
Mělník, Czechia
Site not named
Prague, Czechia
Site not named
Aalborg, Denmark
Site not named
Aarhus, Denmark
Site not named
Copenhagen, Denmark
Site not named
Glostrup Municipality, Denmark
Site not named
Herlev, Denmark
Site not named
Kolding, Denmark
Site not named
Odense, Denmark
Site not named
Angers, France
Site not named
Bordeaux, France
Site not named
Clermont-Ferrand, France
Site not named
Lille, France
Site not named
Nantes, France
Site not named
Paris, France
Site not named
Reims, France
Site not named
Rouen, France
Site not named
Saint-Priest-en-Jarez, France
Site not named
Toulouse, France
Site not named
Bad Ems, Germany
Site not named
Emmendingen, Germany
Site not named
Frankfurt, Germany
Site not named
Freiburg im Breisgau, Germany
Site not named
Hagenow, Germany
Site not named
Hamburg, Germany
Site not named
Koblenz, Germany
Site not named
Rheinfelden, Germany
Site not named
Trier, Germany
Site not named
Uetersen, Germany
Site not named
Athens, Greece
Site not named
Larissa, Greece
Site not named
Pátrai, Greece
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.